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Abstract
Neuropsychiatric disorders overlap in symptoms and share genetic risk factors, challenging their current classification into
distinct diagnostic categories. Novel cross-disorder approaches are needed to improve our understanding of the
heterogeneous nature of neuropsychiatric diseases and overcome existing bottlenecks in their diagnosis and treatment. Here
we employ high-content multi-parameter phospho-specific flow cytometry, fluorescent cell barcoding and automated sample
preparation to characterize ex vivo signaling network responses (n= 1764) measured at the single-cell level in B and T
lymphocytes across patients diagnosed with four major neuropsychiatric disorders: autism spectrum condition (ASC),
bipolar disorder (BD), major depressive disorder (MDD), and schizophrenia (SCZ; n= 25 each), alongside matched healthy
controls (n= 100). We identified 25 nodes (individual cell subtype–epitope–ligand combinations) significantly altered
relative to the control group, with variable overlap between different neuropsychiatric diseases and heterogeneously
expressed at the level of each individual patient. Reconstruction of the diagnostic categories from the altered nodes revealed
an overlapping neuropsychiatric spectrum extending from MDD on one end, through BD and SCZ, to ASC on the other end.
Network analysis showed that although the pathway structure of the epitopes was broadly preserved across the clinical
groups, there were multiple discrete alterations in network connectivity, such as disconnections within the antigen/integrin
receptor pathway and increased negative regulation within the Akt1 pathway in CD4+ T cells from ASC and SCZ patients,
in addition to increased correlation of Stat1 (pY701) and Stat5 (pY694) responses in B cells from BD and MDD patients.
Our results support the “dimensional” approach to neuropsychiatric disease classification and suggest potential novel drug
targets along the neuropsychiatric spectrum.
Introduction
Neuropsychiatric diagnoses do not fall into discrete clinical
groups. They represent a spectrum of conditions with
overlapping symptoms shared across different clinical
dimensions [1, 2]. The persistent and formidable difficulties
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associated with neuropsychiatric nosology are profound,
with distinctions between bipolar and unipolar depression
or autism and childhood schizophrenia being formally
recognized only since the 1950s and 1970s respectively [3,
4]. Today, 20% of individuals who meet the criteria for one
condition in the Diagnostic and Statistical Manual of Mental
Disorders IV (DSM-IV) [5] also fulfill the criteria for at
least two more [2]. Moreover, the decision to class a patient
in a given diagnostic group is based on subjective obser-
vations of behavioral symptoms at the discretion of medical
practitioners and is not an objective measure of biological
etiology [6]. This results in a lack of diagnostic stability,
exemplified by up to 50% of psychotic patients switching
diagnosis over a 10 year period [7], and highlights the fact
that differential diagnosis is a more persistent bottleneck in
clinical psychiatry relative to case–control definition. In
many cases, the diagnosis is ultimately defined by relative
response to treatment following successive rounds of
pharmacological titration across different drug classes [8].
This process can have a devastating effect on patient quality
of life, with only 40–60% of patients achieving substantial
remission of symptoms [9]. Furthermore, due to the limited
understanding of the heterogeneous pathophysiology of
neuropsychiatric diseases, incomplete characterization of
the molecular targets of existing drugs and a lack of relevant
preclinical models, mechanistically novel drug entities with
the potential to address treatment resistance have not been
forthcoming.
While recent advances of genetic association data have
provided unprecedented insights into the potential mole-
cular mechanisms underlying neuropsychiatric pathogenesis
and drug action, aggregate genomic risk profiling of single-
nucleotide polymorphisms (SNPs) still only accounts for a
small proportion (0.17–0.28) of disease liability relative to
the heritable risk (0.37–0.81) observed in monozygotic twin
and family studies across different conditions, including
autism spectrum condition (ASC), bipolar disorder (BD),
major depressive disorder (MDD), schizophrenia (SCZ),
and attention-deficit hyperactivity disorder (ADHD) [10].
Furthermore, the discovery that each neuropsychiatric
patient has a different combination of common but weak, or
rare but highly penetrant, risk alleles [11–13] highlights the
challenge of identifying points of functional convergence
which represent potentially meaningful molecular drug
targets. This difficulty is further compounded by the fact
that genetic risk alleles are often shared between related
neuropsychiatric conditions [10], as exemplified by the
finding that voltage-gated calcium channel subunits CAC-
NA1C and CACNB2 were amongst the top loci implicated
in a combined cohort of five different neuropsychiatric
diseases (BD, MDD, SCZ, ASC, and ADHD) relative to
controls [14]. Thus, one of the primary challenges to ade-
quately contextualizing neuropsychiatric drug target
selection is determining which functional targets are unique
to a given condition and which are shared between multiple
conditions. The second imperative challenge, as the
dimensionality of the molecular landscape of neu-
ropsychiatric diseases becomes apparent, is to find a means
of placing individual patients with partially overlapping
symptomatology into therapeutic categories that align more
closely with treatment response. In order to address these
challenges, it is necessary to progress from the single dis-
ease case–control design, prevalent in many molecular
profiling studies, and explore multiple neuropsychiatric
diseases in parallel at the level of drug target identification.
Given their genomic complexity and the difficulties of
accessing live human brain tissue, there has been a paucity of
relevant cellular models in which to explore functional
alterations in cellular physiology and drug response in neu-
ropsychiatric conditions. However, evidence suggesting that
neuropsychiatric conditions are systemic with functional
alterations of cellular physiology manifested in the central
nervous system (CNS) as well as peripheral tissues [15–17],
has provided new opportunities to address these obstacles.
One such strategy, using induced pluripotent stem cell (iPSC)
technology, involves the reprogramming of peripheral
somatic cells from neuropsychiatric patients to CNS lineage
cells. While this has offered novel insights into cellular
pathology and drug treatment response [18–20], this approach
is limited by relatively high cost, low throughput and phe-
notypic inconsistencies arising from extended cell culture
protocols [21, 22]. In addition, functional characterization of
iPSC-derived neuronal lineages has focused on a limited
number of readouts (e.g., electrophysiology or neuro-
transmitter release) relating to pre-existing hypotheses [23]. In
contrast, native peripheral blood mononuclear cells (PBMCs)
are a readily accessible primary tissue which has been shown
to express many CNS receptors and downstream signaling
proteins which are implicated in neuropsychiatric disease
[24, 25]. Furthermore, a recent genome-wide association
study (GWAS) suggested the enrichment of SNPs associated
with neuropsychiatric (SCZ) risk loci within PBMC subtype
(B cell)-specific gene expression enhancers [11]. Moreover,
evidence that peripheral alterations can induce functional
changes in the CNS with corresponding behavioral sympto-
matology (e.g., psychotic symptoms linked to gut microbiome
alterations [26] or depressive-like symptoms following pro-
inflammatory cytokine release during microbial infection
[27, 28]) suggests that peripheral cellular models might not be
confined solely to surrogate identification of CNS targets, but
might also represent underlying pathophysiological mechan-
isms. Importantly, PBMCs are amenable to high-content
functional screening allowing unbiased examination of a wide
range of cellular response mechanisms, as evidenced by
parallel applications in hematological malignancies [29] and
autoimmune conditions [30].
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Exploration of functional alterations which reflect the
disease state, in neuropsychiatric patient PBMCs, could
have important implications for overcoming present obsta-
cles in neuropsychiatric drug target identification. First,
functional testing in live cells has the potential to reveal
relevant disease-specific alterations in cell signaling net-
works which are not detectable by quantification of basal
protein levels in the resting state, including regulatory and
homeostatic mechanisms [29]. Second, the focus on cellular
responses provides the opportunity to summarize complex
genetic risk factors, with heterogeneous manifestations, as
integrated phenotypes which are more amenable to drug
screening [31]. Third, targeting of key functional mediators
within the cell, such as protein kinases, phosphatases, ion
channels, and G protein-coupled receptors, represents a
heuristic screening method focused on the most “drug-
gable” part of the genome [32]. Finally, the use of primary
cells from patients at the initial stage of drug target identi-
fication could potentially yield a higher success rate of
candidate compounds in subsequent stages of the drug
discovery pipeline [33].
Here we apply high-content, single-cell screening of
functional ligand–receptor interactions and downstream
signaling mechanisms [25, 34, 35] to explore differences in
cell signaling dynamics across the neuropsychiatric spec-
trum using primary PBMCs ex vivo from four major disease
indications (ASC, BD, MDD, and SCZ; n= 100 patients,
25 per diagnosis) in addition to matched typical controls
(n= 100). We employ multi-parameter phospho-specific
flow cytometry [35], fluorescent cell barcoding [34], and
automated sample preparation to simultaneously measure
the activation of 42 intracellular signaling epitopes (span-
ning key CNS and immune cell signaling pathways such as
Akt/GSK-3β, JAK/STAT, MAPK, PKA, PKC, IL-1R/TLR,
and T/B cell receptor (TCR/BCR) signaling) in response to
14 functional ligand conditions (including CNS receptor
agonists, antigens, cytokines, and intracellular signaling
modulators) in three PBMC cell subtypes (CD4+ T cells
(CD3+CD4+), CD4− T cells (CD3+CD4−), and pre-
dominantly B cells (CD3−)). This provided a functional
matrix of 1764 unique cell subtype–epitope–ligand combi-
nations (“nodes”), in addition to the basal expression levels
of each epitope per cell subtype, measured in each PBMC
sample across the five clinical groups. We explore the utility
of this functional array in three ways. First, we assess the
degree of overlap between the cell signaling profile of dif-
ferent neuropsychiatric conditions relative to each other and
controls, based on individual donor readouts. Second, we
examine the cell signaling nodes that were most sig-
nificantly altered in one or more disease indication(s) for
each PBMC cell subtype. Finally, we explore putative
alterations in cell signaling network connectivity across
each of the major neuropsychiatric conditions.
Materials and methods
Clinical sample recruitment
Patients and matched typical control PBMC donors were
recruited as follows: ASC (Cambridge Autism Research
Centre, Cambridge University, Cambridge, UK; n= 25/
group), BD (Foundation Biological Psychiatry, Sofia, Bul-
garia; n= 13 patients and n= 15 controls; and Union
House, Cambridgeshire and Peterborough Mental Health
Foundation Trust, Cambridge, UK; n= 12 patients and 10
controls), MDD (Westfälische Wilhelms University Hos-
pital, Münster, Germany; n= 25/group), and first-onset
antipsychotic drug-naïve SCZ (University Hospital Mar-
qués de Valdecilla, Santander, Spain; n= 25/group;
Tables S3 and S4). In the BD cohort, patients and respective
controls from different clinical centers were matched within
and between centers for age, sex, and body mass index
(BMI). The medical faculty ethical committees responsible
for the respective sample collection sites approved the study
protocols. Informed consent was given in writing by all
participants and clinical investigations were conducted
according to the Declaration of Helsinki [36] and Standards
for Reporting of Diagnostic Accuracy [37].
Diagnoses of neuropsychiatric pathology were conducted
by experienced psychiatrists and were based on the Diag-
nostic and Statistical Manual of Mental Disorders-IV-Text
Revision (DSM-IV-TR) [5]. The exclusion criteria for
patients and controls included: age below 18 years old,
additional neuropsychiatric diagnoses, other neurological
conditions including epilepsy, mental retardation, multiple
sclerosis, immune/autoimmune conditions, infectious disease,
metabolic conditions including diabetes, obesity, cardiovas-
cular disease, hepatic and renal insufficiency, gastrointestinal
conditions, endocrine conditions including hypo-/hyperthyr-
oidism and hypo-/hypercortisolism, respiratory diseases,
cancer, severe trauma, substance abuse including psycho-
tropic drugs and alcohol, somatic medication for non-CNS
indications with CNS side-effects and somatic medication
affecting the immune system including glucocorticoids, anti-
inflammatory/immuno-modulating drugs, and antibiotics.
PBMC isolation and culture
PBMCs were prepared within 4 h from blood collected into
7.5 ml sodium heparin tubes (BD Biosciences; ASC, BD,
and MDD) or acid citrate dextrose solution A tubes (BD
Biosciences; SCZ). Whole blood was pelleted at 500 g for
10 min to remove platelet-rich plasma, diluted 1:1 with
Dulbecco’s phosphate-buffered saline solution (PBS;
Sigma-Aldrich) and centrifuged over Ficoll-Paque PLUS
(GE Healthcare) at 750 g for 20 min at 23°C (15 min at
1000 g for BD samples from Sofia). PBMCs were extracted
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from the interphase, washed three times with PBS at 300 g
for 10 min (once at 760 g for 10 min for BD samples from
Sofia) and cryopreserved at 5*106 cells/ml in heat-
inactivated fetal bovine serum (FBS; Sigma-Aldrich)
(Roswell Park Memorial Institute (RPMI)-1640 medium
with 25 mM Hepes, Ultraglutamin-1, 10% FBS and 1%
penicillin–streptomycin for BD samples from Sofia) con-
taining 10% dimethyl sulfoxide (DMSO; Sigma-Aldrich).
PBMCs were thawed at 37°C and resuspended in sterile
conditions in complete RPMI media with deoxyr-
ibonuclease (DNAse) (RPMI-1640 with sodium bicarbonate
(Sigma-Aldrich), 10% FBS (Life Technologies), 50 U/ml
penicillin and 50 µg/ml streptomycin (Life Technologies),
2 mM L-alanyl-L-glutamine dipeptide (Life Technologies),
and 20 µg/ml DNAse (Sigma-Aldrich)). The cells were
counted using a Coulter Counter (Beckman Coulter), pel-
leted and resuspended at 2*106 cells/ml. The cells were
strained via a 40 µm cell strainer (Corning) and rested for
24 h at 37°C/5% CO2 in 96-well polypropylene plates
(Starlab). Samples from participants from different clinical
groups (n= 200), alongside QC samples (n= 16) from a
single typical control donor, were randomized across dif-
ferent plates, plate positions and experimental days to
minimize measurement-related batch effects.
Preparation of functional ligands
Ligands (n= 14) used to stimulate PBMCs were selected
following an initial screen of 56 stimulants [25] and
included broad-range as well as specific cell signaling
activators/inhibitors, cell type-specific antigens, and CNS
receptor agonists/antagonists. Ligands were purchased from
BD Biosciences, Sigma-Aldrich, Tocris/Bio-Techne,
eBioscience/Affymetrix, Life Technologies, Antibodies-
online, and Enzo Life Sciences. JB1121 was synthesized
following published protocols [38] and supplied courtesy of
Joshua A. Bishop, Tracey Petryshen, and Steven J.
Haggarty from Harvard Medical School (Boston, MA,
USA). Table S1 lists the ligands used with their primary
mechanisms of action and final assay concentrations
(selected based on published in vitro efficacy data). Stock
solutions of ligands were prepared in sterile conditions.
Initial solubilization was achieved using DMSO (for small
molecules) or PBS (for biologicals). Intermediate dilutions
were made in PBS and DMSO was added to equivalent
amounts for each ligand and vehicle. All stocks and dilu-
tions of ligands were stored at −80°C and repeated
freeze–thaw cycles were avoided.
Stimulation of PBMCs
Stimulation is defined broadly as the exposure of PBMCs to
a ligand which has the potential to perturb the resting
state cell signaling dynamics by either increasing or
decreasing the expression of cell signaling epitopes.
PBMCs were pelleted and resuspended in 96-well poly-
propylene plates using complete RPMI media without
penicillin–streptomycin at 3*106 cells/ml. The cells were
rested for 45 min at 37°C before ligand exposure.
Ligands and vehicle were reconstituted in complete
RPMI media without penicillin–streptomycin and added to
the cells using a Biomek NX liquid handler (Beckman
Coulter) with integrated compact shaker–heater–cooler
system (Inheco). The final concentration of DMSO was
0.1%. Vehicle wells represented one eighth of the total
wells assayed and were spaced evenly across each 96-well
plate. The cells were exposed to the ligands at 37°C for
30 min. For wells treated with the anti-CD3/CD28-XL
ligands, the final 2 min of the resting period were used to
pre-incubate the cells with biotinylated anti-CD3 (OKT3)/
anti-CD28 (CD28.2) antibodies (eBioscience), before cross-
linking them using neutravidin (Life Technologies) in the
stimulation step. Ligand exposure was halted by fixation for
10 min at 37°C using paraformaldehyde (Sigma-Aldrich) in
PBS at a final concentration of 1.6%.
Fluorescent cell barcoding
Stock solutions of barcoding dyes CBD 450 (BD Bios-
ciences) and CBD 500 (BD Biosciences) were prepared as
per the manufacturer’s instructions in DMSO in poly-
propylene 96-well plates and stored at −80°C. Different
combinations of the dyes were used to produce 16 barcoded
cell populations resolved using final concentrations of CBD
450 (0.000, 0.015, 0.050, 0.150 mg/ml) combined with
CBD 500 (0.000, 0.038, 0.125, 0.375 mg/ml; Figure S1).
Fixed cells were washed with PBS and permeabilized in
100 µl ice cold methanol (Fisher Chemical) for 20 min at
2°C using a Biomek NX liquid handler. The barcoding dyes
were diluted in ice cold PBS and 100 µl/well was added to
the suspension of cells in methanol. The final concentration
of DMSO from the barcoding dyes at this stage was 3.5%.
The barcoding reaction was incubated in the dark for 30 min
at 2°C and the cells were washed five times in ice cold
FACS buffer (PBS with 0.5% bovine serum albumin
(Sigma-Aldrich)). The barcoded cells from individual
donors were pooled and pelleted.
Intracellular staining of cell signaling epitopes in
PBMC subsets
The pooled fixed-permeabilized-barcoded cells were resus-
pended in 100 µl of FACS buffer containing 20% human Fc
receptor binding inhibitor (eBioscience) and incubated for
20 min at room temperature in the dark. The cells were
stained using 1 µl/ml anti-human CD3 (UCHT1) PE-Cy7
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(eBioscience) and 1 µl/ml anti-human CD4 (SK3) PerCP-
eFluor710 (eBioscience) and distributed across a 96-well
polypropylene plate. The cells were stained using a Biomek
NX liquid handler with fluorescently conjugated anti-
human antibodies against intracellular signaling epitopes
(Table S2) for 45 min in the dark at room temperature, as
per the manufacturer’s instructions. Antibodies against
intracellular epitopes were purchased from BD Biosciences,
Cell Signaling Technology and Merck Millipore and were
used in groups of three antibodies per plex. The cells were
washed twice and resuspended in FACS buffer at 2*106
cells/ml for acquisition.
Data acquisition using flow cytometry
PBMC cell suspensions were acquired using an eight color
FACSVerse flow cytometer (BD Biosciences) with 405,
488, and 640 nm laser excitation at an average flow rate of
2 µl/s and an average threshold event rate of
1000–2000 events/s. Each experiment was done once and
single acquisition was conducted per condition. Multicolor
Cytometer Setup and Tracking beads (BD Biosciences)
were used for QC and standardization of photomultiplier
tube detector voltages across multiple experimental runs.
Fluorescence compensation was conducted using anti-
mouse IgGκ antibody capture beads (Bangs Laboratories)
labeled separately with anti-human CD3 (UCHT1) PE-Cy7,
anti-human CD4 (SK3) PerCP-eFluor-710, anti-human
Stat3 (pY705) (4/P-STAT3) AlexaFluor488 (AF 488; BD
Biosciences), anti-human Stat3 (pY705) (4/P-STAT3) PE
(BD Biosciences), and anti-human Stat3 (pY705) (4/P-
STAT3) AlexaFluor647 (AF 647; BD Biosciences),
alongside single-stain controls with maximum and mini-
mum concentrations of each barcoding dye per PBMC
sample.
Statistical data analysis
Flow cytometry data was analyzed in FCS 3.0 file format
using Flow Jo v.10.0.8 software (Tree Star). Statistical
analysis was conducted using R v.3.3.0 software (R Core
Team) [39] and GraphPad Prism 5 (GraphPad Software
Inc.). Sample sizes were chosen based on previous work
[25]. PBMC samples in which the lymphocyte gate con-
tained less than 30% of events, measured by forward
scatter (FSC-A)/side scatter (SSC-A), were excluded from
further analysis. Experimental variables including posi-
tional effects within and across 96-well plates, barcoding
dye fluorescence spillover, sample viability, cell counts,
clinical group, and sample source were investigated using
principal component analysis (Figure S2). Batch effects in
median fluorescence intensities (MFIs) caused by running
samples from different countries of origin and on different
days were normalized for each epitope and barcode using
the empirical Bayes algorithm—ComBat (R “sva” pack-
age; Figure S3) [40, 41], which is well established for
removing sample origin and batch effects in a range of
high-impact studies [42–49]. Matching of clinical groups
was conducted using the Wilcoxon rank-sum test
(Kruskal–Wallis test for more than two groups) for con-
tinuous variables or the Fisher’s exact test (χ2 test for
more than two groups) for categorical variables. The
minimum number of individual PBMC donors included in
any of the comparisons was 15. All statistical tests were
two sided where applicable.
For the determination of ligand activity, the MFIs across
PBMC samples, within each clinical group, cell subtype and
stained epitope, were compared between each ligand and
the vehicle treatment using the mixed effects analysis of
covariance (mixed ANCOVA; accounting for replicate
measurements). Relevant covariates were selected amongst
age, sex, and BMI in a stepwise procedure using Bayesian
Information Criterion. The null distribution was calculated
using permutation procedure (n= 1000 permutations) to
control for small sample numbers, unknown distribution of
the data and the presence of outliers. The same test was also
applied for each ligand per functional fluorescence channel
(AF 488, PE and AF 647) in the unstained condition to
determine whether the ligand activity was an artifact of
fluorescence spillover from adjacent channels or ligand
auto-fluorescence (background fluorescence). In cases
where the ligand MFI was significantly altered with respect
to vehicle MFI in the unstained condition, the epitopes
labeled in the corresponding functional channel were only
counted as active if the MFI response was in a different
direction or had a minimum 10% greater fold change than
the unstained condition. For ligands with significant activity
(permuted P < 0.05) which superseded the background
fluorescence, the response ratio was quantified as the
median MFI of the ligand condition divided by the median
MFI of the vehicle condition across PBMC samples. For
responses <1 (i.e., where the ligand caused a decrease in
MFI with respect to the vehicle), the response is reported as
a negative fold change (−1/response ratio). The stain index
of each antibody, per cell subtype, was calculated across
PBMC samples from all clinical groups, in the absence of
stimulation, as the median MFI of the antibody stained
sample divided by the median MFI of the corresponding
unstained control.
For the comparison of the clinical groups, only nodes
(cell subtype–epitope–ligand combinations) which showed
a significant ligand activity (permuted P < 0.05, adjusted for
background fluorescence) in any of the clinical groups, with
a minimum fold change of 10% (n= 581), in addition to the
basal epitope levels (n= 126), were analyzed. Although
exclusive, this filter ensures that only the most robust nodes
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are reported in the clinical association analysis. Association
of each signaling node MFI to clinical group status was
investigated using a mixed ANCOVA model, accounting
for replicate measurements, after adjusting for covariates.
To account for the unknown distribution of the data, the
small sample size and the presence of outliers, the null
distribution of the test statistic was estimated by randomly
permuting sample labels 1000 times for each node. The
predictive variables of clinical group and ligand presence
were set as interaction term, alongside main effect terms,
within the model to determine epitopes which responded
differently to individual ligand exposures across the clinical
groups (permuted P < 0.05, mixed ANCOVA F-test).
Group status, without interaction, was set as the predictive
variable to identify differences in basal epitope expression
between clinical groups. An additional criterion of non-
permuted
P value < 0.05 was applied to the F-test results to exclude
nodes which gained significance as a result of permutation,
despite being insignificant (P ≥ 0.05) for non-permuted
P value. Pairwise t-test comparisons within the linear
mixed effects model were used to determine which clinical
groups differed significantly from typical controls
(permuted P < 0.05). Optional covariates, age, sex, and BMI
were selected in a stepwise procedure for each node sepa-
rately using Bayesian Information Criterion. For nodes
differing significantly (P < 0.05, mixed ANOVA F-test)
between the four cohorts of 25 control samples, in either the
vehicle or the ligand condition, an additional filter was
applied, including permuted P < 0.05 for the within-cohort
disease-control comparison (mixed ANCOVA F-test; 25
patients vs. 25 controls) and a consistent within-cohort
disease potentiation/attenuation fold change relative to the
between-cohort comparison. Significant nodes have also
been tested for their association with patient medication
status and source of the sample (if samples in given group
originated from more than one location) using mixed
ANCOVA F-test. Q values were calculated using the
Benjamini–Hochberg procedure [50]. Box plots of disease-
associated nodes show interquartile range with the median
(horizontal line) and the minimum and maximum values
(whiskers), excluding outliers (dots).
Correlation network analysis was based on Pearson cor-
relation coefficients between epitope readouts within each cell
type, as implemented in the R “corrr” package v.0.2.1.
Combined readouts from all treatment conditions, including
vehicle, were used to cover a broad range of activities. The
proximity of the epitopes was determined by multi-
dimensional scalingand and the color and transparency of the
connecting lines represent the strength of the correlation.
Data were visualized using Flow Jo, R software,
Excel 2016 (Microsoft), and Adobe Illustrator (Adobe
Systems).
Code availability
Upon request.
Results
Definition of the functional matrix of cell signaling
responses in PBMC subsets
We first sought to examine whether the cell signaling
activity profile of the ligands used in the high-content assay
(Table S1), in terms of epitope and cell subtype specificity
(Table S2, Figure S1) across the clinical groups (Tables S3
and S4) at the 30 min incubation time point [25],
was consistent with previously published data. Positive
controls (calyculin A, PMA/ionomycin, thapsigargin,
and staurosporine) were the most universally active ligands
(P < 0.05, mixed ANCOVA F–test; min. 10% fold change
in epitope expression after adjusting for background fluor-
escence) across cell subtypes (Figure S4), consistent with
their known profile as broad-spectrum cell signaling mod-
ulators [25, 51, 52]. Epitope-specific responses were
observed for JAK-Stat cytokines (IL-6, IL-10, and IFN-α2c)
across different Stat isotypes (Stat1, Stat3, Stat4, Stat5)
[51, 52], for mTORC1 inhibitor (rapamycin) at
mTORC1 substrate 4EBP1 (pT36/pT45) [53] and for cAMP
pathway ligands (forskolin and NECA) at PKA RIIα (pS99)
[54, 55]. Cell subtype-specific responses were observed for
antigen-receptor ligands in CD4+ T cells at SLP-76
(pY128), Zap-70 (pY319)/Syk (pY352), and WIP
(pS488), following T-cell receptor stimulation (anti-CD3/
CD28) [56, 57], and in B cells at IκBα, p38 MAPK (pT180/
pY182), and S6 (pS235/pS236), following B-cell receptor
stimulation (BCR/CD40L) [58, 59]. IL-6 also displayed cell
subtype specificity in terms of the magnitude of phosphor-
ylation induction at Stat1 (pY701), Stat3 (pY705), and Stat5
(pY694) epitopes, which was greatest in CD4+ T cells,
moderate in CD4− T cells, and absent in B cells, consistent
with previous reports [51, 60]. Taken together, these data
suggest that the high-content functional screening assay is
capable of resolving characteristic ligand–epitope response
profiles across the clinical groups.
Subsequently, we compared the total number of cell
signaling responses and their distribution across the differ-
ent PBMC cell subtypes between the clinical groups. The
proportion of active cell signaling responses relative to the
total number of functional nodes measured (n= 1764) was
similar across clinical groups (24–26%; Table S5), with
69–75% of active nodes in each disease showing responses
in the same direction across all groups. The distribution of
significant cell signaling responses across the different cell
subtypes, in terms of the number of active nodes and range
S. G. Lago et al.
of fold changes (FC), was also largely conserved between
the clinical groups, with CD4+ T cells accounting for
34–37% of active nodes (FC −7.5 to 46.5), CD4− T cells
accounting for 32–36% of active nodes (FC −7.5 to 62.6),
and B cells accounting for 30–34% of active nodes (FC
−7.9 to 46.7; Table S5 and Figure S5). Taken together,
these data suggest that any differences between the
PBMC response profiles of the different clinical groups
were likely to be pathway specific and not the result of
widespread changes in the activity of the measured cell
subtypes.
Differences in cell signaling across the
neuropsychiatric spectrum
Having defined which cell signaling nodes were active, we
aimed to identify nodes which showed a significant inter-
action with clinical group status (P < 0.05, mixed
ANCOVA F-test) and were significantly altered in at least
one of the disease groups (ASC, BD, MDD, and SCZ)
relative to typical controls (P < 0.05, pairwise t-test com-
parisons within the linear mixed effects model). Twenty-
five nodes fulfilled these criteria, including 20 responses to
ligand stimulation and the basal expression of five epitopes
(Table S6). We then assessed the distribution of individual
patient diagnoses across the identified panel of neu-
ropsychiatric cell signaling alterations. Unsupervised hier-
archical clustering of individual patient readouts across the
putative disease nodes revealed four main clusters (Fig. 1a).
However, patients from different disease groups did not
segregate exclusively into specific clusters. Instead, they
exhibited a spectral distribution across the clustering hier-
archy with each clinical group showing areas of peak den-
sity in addition to varying degrees of overlap with the other
clinical groups (Fig. 1b). The order of primary peaks across
the disease continuum ranged from MDD on one
end, through BD and SCZ, to ASC on the other end.
There was a high degree of overlap between SCZ and
BD and between BD and MDD, moderate overlap between
SCZ and MDD and between SCZ and ASC, and
little overlap between MDD and ASC and between BD and
ASC.
To contextualize the differences between disease groups
relative to typical controls, we performed linear dis-
criminant analysis on the complete set of assayed nodes
(Fig. 1c). This revealed considerable overlap between all
clinical groups, with typical controls located centrally in the
discriminant space and each disease reflected as an exten-
sion thereof. BD and MDD showed the widest range of
extension in a single direction, while ASC appeared as a
broad “halo” surrounding the control (Ctrl) space. Overlap
of the disease space within the Ctrl area was greatest for
ASC followed by BD, MDD, and lastly SCZ. Importantly,
the area occupied by SCZ overlapped almost entirely with
that of BD and only to a lesser extent with that of the other
diseases. Taken together, these results suggest variable
overlap between the cell signaling repertoires
associated with different neuropsychiatric diseases, which
are heterogeneously expressed at the level of each indivi-
dual patient.
Disease-specific cell signaling responses in PBMC
subsets
Analysis of the putative neuropsychiatric disease nodes at
the level of each individual disease cohort revealed a greater
number of cell signaling alterations in SCZ (14 altered
nodes) relative to MDD (8 nodes), BD (6 nodes), and ASC
(5 nodes; Fig. 2a, Table S6). At the level of each PBMC cell
subtype, more disease-associated nodes were found in B
cells (14 nodes) relative to CD4+ T cells (8 nodes) and
CD4− T cells (3 nodes), although the distribution of these
nodes across the cell subtypes was different dependent on
the disease in question (Fig. 2a, Table S6).
In terms of individual epitopes, we identified cell sig-
naling alterations previously associated with neu-
ropsychiatric conditions including dysregulation of total
Akt1 in SCZ and altered Akt phosphorylation at pT308 in
BD (Fig. 2b). Furthermore, the analysis revealed potentially
novel cell signaling targets such as S6 (pS235/pS236), NF-
κB p65 (pS529), and Stat3 (pS727) which were enriched
among the total set of disease-associated alterations (20%,
12%, and 12% of nodes, respectively, compared to 2.4%
expected by chance). The most significantly associated
nodes per cell subtype revealed functional alterations of
these epitopes which were either unique to single diseases,
for example the attenuated CD4+ T cell response to staur-
osporine at NF-κB p65 (pS529) in SCZ or the potentiated B
cell response to thapsigargin at S6 (pS235/pS236) in MDD,
or shared between multiple diseases, for example the atte-
nuated CD4− T cell response to calyculin at S6 (pS235/
pS236) in BD and SCZ (Fig. 2c). In some cases (e.g., S6
(pS235/pS236)), the same epitope responded differently in
different diseases depending on the stimulant applied and
cell subtype analyzed. Taken together, these findings sug-
gest that there are ligand-specific functional responses that
are altered in one or more neuropsychiatric conditions,
dependent on the cell signaling epitope and PBMC subtype
in question.
Altered cell signaling network connectivity across
neuropsychiatric conditions
Having compared the responses at individual cell signaling
nodes, we sought to explore differences in cell signaling
network connectivity between typical controls and different
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major neuropsychiatric conditions. To do this, we correlated
epitope responses across all ligands and individual PBMC
donors for each clinical group to form putative network
connections and then mapped these onto pathway clusters in
principal component space. In CD4+ T cells (Fig. 3), the
basic pathway cluster structure was preserved across the
clinical groups. However, the data revealed alterations in
cell signaling network connectivity (Pearson’s r ≥ 0.8 or
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Fig. 1 Individual patient differences in cell signaling across the neu-
ropsychiatric spectrum. a Hierarchical clustering of individual patient
(x axis) peripheral blood mononuclear cell (PBMC) readouts for nodes
(defined as cell subtype–epitope–ligand combinations; y axis) which
showed a significant association with clinical group status (i.e., sig-
nificant (P < 0.05) interaction between ligand treatment and clinical
status for ligand responses or significant main effect of clinical group
for basal epitope expression in mixed ANCOVA F-test) and were
significantly altered in at least one of the clinical groups (autism
spectrum condition (ASC), bipolar disorder (BD), major depressive
disorder (MDD) or schizophrenia (SCZ)) relative to typical controls
(Ctrl; P < 0.05, pairwise t‑test comparisons within the linear mixed
effects model). These included 20 ligand responses and five basal
epitope expression levels. Nodes involving response to ligand were
filtered for activity in at least one of the clinically associated groups, as
described in Materials and methods. Legend reflects ratio of epitope
median fluorescence intensity (MFI) of the ligand treatment to mean
epitope MFI of the vehicle treatment (for ligand responses) or ratio of
mean epitope MFI of the vehicle condition to mean epitope MFI of the
vehicle condition in the control group (for basal epitope expression)
per condition and sample, standardized to mean control levels and
scaled across all nodes. Ligand abbreviations: BCR/CD40L, B-cell
receptor stimulant/-MegaCD40 ligand; PMA/I, phorbol 12-myristate
13-acetate/ionomycin; SP, staurosporine; TG, thapsigargin.
b Spectral summary of cell signaling overlap between different
neuropsychiatric diseases. Kernel density estimates were derived from
the hierarchical clustering order (a) to reflect the probability distribu-
tions of each condition across the clustering hierarchy. c Linear dis-
criminant analysis on complete set of assayed nodes, including ligand
response nodes (n= 1764) and basal epitope levels (n= 126), for all
clinical groups. Dots reflect individual donors and shaded areas reflect
95% confidence intervals for each clinical group. Data in each panel
(a–c) is color-coded in terms of clinical group identities with PBMC
sample numbers as follows: autism spectrum condition (green;
n= 25), bipolar disorder (gold; n= 25), major depressive disorder
(purple; n= 25), schizophrenia (magenta; n= 25), and typical control
(blue; n= 100)
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≤−0.8) for specific conditions relative to controls. Network
disconnectivity was observed within the antigen/integrin
(A/I) receptor pathway cluster for SCZ at IκBα–PKC-α (1)
and Src (pY418)–PKA RIIα (pS99) (2), for SCZ and ASC
at CrkL (pY207)–Pyk2 (pY402)–Src (pY418) (3), and for
BD at PLC-γ1–PLC-γ2 (4). MDD did not show any missing
epitope correlations relative to controls. Conversely, other
areas of the cell signaling network showed increased con-
nectivity in specific diseases relative to controls. This
included an increasing number of negatively correlated
connections between total Akt1 and adjacent epitopes in the
Akt pathway cluster for MDD, SCZ, and ASC successively
(5) and an additional positively correlated connection at
PLC-γ1–Src (pY418) for SCZ and ASC in the A/I receptor
cluster (6).
Likewise, in the other PBMC cell subtypes, while the basic
pathway cluster structure was preserved between clinical
groups, there were notable disease-specific alterations in cell
signaling correlation networks. In CD4− cells (Figure S6),
these included the disruption of an alternating positive and
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negative correlation loop at S6 (pS235/pS236)-IκBα in BD
and ASC (1), uncoupling of Akt and A/I receptor clusters at
PKA RIIβ (pS114) in BD (2), the absence of multiple Stat3
(pS727) connections in SCZ (3) and increased connections to
Zap-70 (pY319)/Syk (pY352) (4) and PKC-θ (5) in ASC. In B
cells (Figure S7), these included increased correlation of Stat1
(pY701) with Stat5 (pY694) in BD and MDD (1), uncoupling
of Akt and A/I receptor clusters at PKA RIIβ (pS114) in SCZ
(2) and disruption of the connection between ERK1/2 (pT202/
pY204) and p120 Catenin (pT310) in BD (3). Taken together,
these findings suggest that while the cluster structure of the
epitopes within the principal component space is broadly
preserved across the clinical groups, there are multiple
alterations in the activity-dependent correlation of basal and
induced cell signaling epitopes in different neuropsychiatric
conditions relative to controls and each other.
Discussion
The current classification of neuropsychiatric conditions
reflects clinical syndromes with largely unknown etiology
[61, 62]. In this work, we apply high-content functional
screening of primary PBMCs from neuropsychiatric
patients and typical controls to functionally interrogate the
underlying cell signaling structure of different diseases
across the neuropsychiatric spectrum. This has a number of
implications with respect to interpreting previous molecular
profiling analyses and the provision of relevant cellular
models for novel drug discovery.
Analysis of individual patient readouts revealed several
features in terms of the relative overlap in cell signaling
profiles of different neuropsychiatric conditions. First,
clustering of individual patient readouts across clinically
associated nodes (Fig. 1a) displayed a spectral arrangement
(Fig. 1b) of primary peak densities ranging from MDD,
through BD and SCZ, to ASC. The overlap of the cell
signaling alterations in the different conditions, represented
by the proximity of their respective peaks, is largely con-
sistent with the genetic overlap suggested by genome-wide
SNP-based genetic correlation studies [9, 10]. This includes
a high degree of overlap between SCZ and BD and between
BD and MDD, followed by moderate overlap between SCZ
and MDD, and SCZ and ASC, and little overlap between
MDD and ASC, and BD and ASC. Second, SCZ was the
only disease to show a biphasic spectral distribution with a
prominent secondary peak within the principal peak areas of
MDD and BD. Although we found no significant differ-
ences in clinical variables between the two SCZ clusters,
this is concurrent with previous studies suggesting hetero-
geneity in the clinical characteristics of SCZ [9] and the
existence of subgroups of patients with distinct molecular
pathophysiology [63, 64]. Third, the shallow peak of MDD
and wide distribution of MDD patients across the spectrum
is consistent with previous reports of increased variation in
the molecular etiology of MDD relative to other neu-
ropsychiatric conditions [10]. Finally, although the spectral
analysis is useful to determine the relative overlap between
the cell signaling profiles of different neuropsychiatric
conditions, it enforces a sequential arrangement of the
conditions. The linear discriminant analysis (Fig. 1c) further
contextualizes this arrangement as a dimensional extension
of typical controls.
The present results confirm, but also extend, existing
hypotheses of cell signaling alterations in neuropsychiatric
conditions. The observed reduction in basal levels of total
Akt1 protein in B cells in SCZ (Fig. 2b) is consistent with
previous reports in B lymphoblastoid cell lines and post-
mortem brain frontal cortex samples from SCZ patients,
relative to controls [65], and reports of sensory-motor gat-
ing deficits, reminiscent of perceptual alterations in SCZ, in
Fig. 2 Comparison of disease-specific cell signaling responses in
peripheral blood mononuclear cell (PBMC) subsets. a Disease-
associated cell signaling nodes per PBMC cell subtype. Shows
nodes (defined as cell subtype–epitope–ligand combinations) which
displayed a significant association with disease group status (ligand
treatment–clinical status interaction P < 0.05 for ligand responses or
main effect of clinical status P < 0.05 for basal epitope levels in mixed
ANCOVA F–test) and were significantly altered in at least one of the
disease groups (autism spectrum condition (ASC), bipolar disorder
(BD), major depressive disorder (MDD), or schizophrenia (SCZ),
n= 25 each) relative to typical controls (Ctrl, n= 100; P < 0.05,
pairwise t-test comparisons within the linear mixed effects model).
Y axes show a -log10 transformation of P values for node associations
between a single disease and the control group from pairwise t-test
comparisons within the linear mixed effects model. X axes show log2-
transformed fold changes (FC) between a single disease and the
control group defined for ligand responses as an absolute value of
(1−ligand response in disease group)/(1−ligand response in control
group) and for basal epitope levels as median epitope MFI (median
fluorescence intensity) for the vehicle condition in the disease group/
median epitope MFI for the vehicle condition in the control group. For
the majority of ligand responses, this represents a means of expressing
the relative potentiation (log2FC > 0) or attenuation (log2FC < 0) of
response independently of its direction. Nodes involving response to
ligand were filtered for activity in at least one of the clinically asso-
ciated groups, as described in Materials and methods. Significant
nodes are annotated and color–coded in terms of clinical group iden-
tities: ASC (green), BD (gold), MDD (purple), and SCZ (magenta).
Ligand abbreviations: BCR/CD40L, B cell receptor stimulant/
MegaCD40 ligand; PMA/I, phorbol 12-myristate 13-acetate/ionomy-
cin; SP, staurosporine; and TG, thapsigargin. b Dysregulation of
putative neuropsychiatric drug targets Akt1 in SCZ (panels 1–2) and
Akt (pT308) in BD (panel 3) in B cells. Plots show MFI of epitope
expression (y axis) per clinical group (x axis) under basal (vehicle;
blue) or ligand stimulation (yellow) conditions. Shows interaction
P value for ligand responses and main effect of clinical status P value
for basal epitope expression (pairwise t-test within the linear mixed
effects model). c Five-group representation of the most significant
clinically associated nodes (mixed ANCOVA F-test) in each cell
subtype. Plots show MFI of epitope expression (y axis) per clinical
group (x axis) under basal (vehicle; blue) or ligand stimulation
(yellow) conditions. Upper P values are derived from mixed
ANCOVA F-test and lower P values reflect pairwise t-test compar-
isons vs. control group within the linear mixed effects model
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Akt1−/− mice [66]. Furthermore, the present results suggest
that Akt1 is functionally dysregulated in SCZ. This is evi-
dent from the attenuated response of Akt1 to calyculin A
(Fig. 2b) and the increased number of negative correlations
between Akt1 and adjacent proteins in the network analysis
(Fig. 3). Previous analyses of phospho-specific cell
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signaling responses suggest that decreases in total protein
detection following widespread pathway activation are
potentially indicative of negative feedback regulation [25].
Taken together, these findings suggest that previous
observations of decreased Akt1 in SCZ are not solely the
result of decreased protein expression but are also poten-
tially influenced by an increased negative feedback reg-
ulation of the protein in the context of wider signaling
network activation. Interestingly, this feature was also
shared by ASC and to a lesser extent MDD in the network
analysis, suggesting convergent disease mechanisms at the
functional level. In contrast, dysregulation of Akt in BD
was observed in terms of increased changes in phosphor-
ylation at the Akt activation site pT308 (Fig. 2b) but not in
terms of changes in total protein levels or network dysre-
gulation. This is consistent with recent data suggesting that
Akt (pT308) is one of the mechanistic targets of the mood
stabilizer lithium used to treat BD [67]. Thus, while the
present results confirm previous reports of Akt pathway
alterations as a common feature of different neuropsychia-
tric conditions, they suggest that the nature of the altera-
tions, in terms of epitope specificity and regulatory
relationships within the cell signaling network, is very dif-
ferent. The results also reveal the importance of using high-
content analysis to simultaneously relate changes in total
protein levels with those of key phospho-activation sites, a
feature recently suggested to be crucial in defining the
mechanistic implications of drug response in iPSC-derived
neurons of neuropsychiatric patients [68].
In addition to characterizing cell signaling pathways
already implicated as primary mediators of neuropsychiatric
pathogenesis and drug efficacy, the present results also
revealed novel cell signaling targets, S6 (pS235/pS236),
NF-κB p65 (pS529), and Stat3 (pS727) (Fig. 2c and
Table S6), which were more significantly associated to
neuropsychiatric disease. Nodes displaying alterations in
NF-κB p65 (pS529) and Stat3 (pS727) activity were shared
almost exclusively between SCZ and MDD (P= 1.8*10-5,
Fisher’s exact test probability that overlap occurs by
chance). This raises the possibility that NF-κB p65 (pS529)
and Stat3 (pS727) might represent a shared substrate for
negative symptomatology present in both SCZ and MDD.
The identified alterations in NF-κB p65 signaling in PBMCs
are consistent with previously reported changes in NF-κB
expression in post-mortem brain samples of patients with
SCZ [69–71] and MDD [72] and with reports that poly-
morphisms in the NFKB1 gene are risk factors for
treatment-refractory SCZ [73] and suicide [74]. Con-
currently, microglial cell-specific Stat3−/− knockout mice
have been reported to show alterations in depressive-like
behavior in animal models of major depression [75]. NF-κB
and Stat3 are also primary mediators of pro-inflammatory
cytokine signaling (e.g., IL-1β, TNF-α, and IL-6) associated
with negative symptomatology in both SCZ [63, 76] and
MDD [77, 78]. It is possible that these cell signaling
alterations in PBMCs in SCZ and MDD are either the result
of chronic stimulation with elevated circulating pro-
inflammatory cytokines [15, 77] or represent intrinsic cel-
lular phenotypes which are the cause of increased pro-
inflammatory cytokine transcription.
The biological implications of these nodes in neu-
ropsychiatric diseases may also extend beyond their invol-
vement in pro-inflammatory pathways. Stat3 has also been
shown to regulate the activity-dependent expression and
function of key GPCRs and neurotransmitter transporters
(e.g., 5HT-2A, β-adreno, GABA, mAch, NMDA, and
AMPA receptors [79–82] and the serotonin transporter [83])
in neuronal cells and mediate processes which are report-
edly altered neuropsychiatric pathogenesis in the brain (e.g.,
synaptic plasticity [79], neurogenesis, astrogliogenesis,
axonal remodeling [81, 82] and microglial activation [84]).
Conversely, NF-κB is reported to mediate the effects of
hypothalamic–pituitary–adrenal (HPA) axis dysregulation
on stress-induced anhedonia and impaired neurogenesis
[85, 86], in addition to regulating the balance between
neuroprotective and pro-apoptotic mechanisms in the CNS
via NLRP1/NLRP3 inflammasome regulation [87, 88].
Interestingly, modulators of Stat3 (e.g., minocycline, with-
aferin A, and curcumin) [89–91] and NF-κB (e.g., celecoxib
and aspirin) [92, 93] function are currently in clinical trials
or have shown efficacy as adjunctive therapies for treating
subtypes of neuropsychiatric symptoms, including
treatment-resistant negative symptoms in SCZ. This sug-
gests that, in addition to their mechanistic relevance within
the CNS, they may also constitute feasible novel drug
targets.
Fig. 3 Altered functional correlation structure of cell signaling net-
works in neuropsychiatric conditions. Cell signaling epitope responses
in CD4+ T cells were correlated using data from all ligands and
individual donors in each clinical group including (a) typical controls
(Ctrl; n= 100), b bipolar disorder (BD; n= 25), c major depressive
disorder (MDD; n= 25), d schizophrenia (SCZ; n= 25), and e autism
spectrum condition (ASC; n= 25). Positive or negative correlations
are represented as red or blue connections between epitopes respec-
tively. Legend shows the strength of correlations expressed as Person
correlation coefficient, ρ. Only correlations which exceed the Pear-
son’s ρ threshold (≤−0.8 or ≥0.8) are shown. Epitopes are mapped
onto broad signaling pathway clusters, annotated with common
functionality (Akt, JAK/STAT, antigen/integrin (A/I) receptor, and
WIP/ERK), in principal component space. Putative network dis-
connections present in one or more diseases are labeled as follows:
IκBα–PKC-α (1), Src (pY418)–PKA RIIα (pS99) (2), CrkL
(pY207)–Pyk2 (pY402)–Src (pY418) (3), and PLC-γ1–PLC-γ2 (4).
Increased putative network connections include Akt1 with adjacent
epitopes (5) and Src (pY418)–PLC-γ1 (6). Phosphorylation sites for
each protein are abbreviated to ‘p’ for representation and listed in
Table S2. Proteins with two phosphorylation sites are abbreviated:
pAkt(1), Akt (pT308); pAkt(2), Akt (pS473); pStat1(1), Stat1
(pY701); pStat1(2), Stat1 (pS727); pStat3(1), Stat3 (pY705); pStat3
(2), Stat3 (pS727)
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The altered phosphorylation responses at S6 (pS235/
pS236) in PBMCs are consistent with previous reports of
alterations in direct upstream kinases (p70 S6 kinase and
p90 S6 kinase) in human post-mortem brain samples of
neuropsychiatric patients [94, 95] and behavioral effects in
animal models [96–101] of neuropsychiatric diseases.
Downstream of mechanistic target of rapamycin complex 1
(mTORC1), the S6 protein represents a key mediator of
neuronal activity-dependent synaptic protein synthesis
which is implicated in altered synaptic long-term potentia-
tion and long-term depression in different neuropsychiatric
disorders [96, 102, 103]. S6 is also involved in modifying
adult hippocampal neurogenesis following interactions
between GABAergic signaling and neuropsychiatric risk
genes in mice [103]. Importantly, the activity of S6 and
upstream kinases has been shown to mediate the efficacy of
antipsychotic, antidepressant and mood stabilizing drugs
[104–106] including several with novel mechanisms of
actions [106–110].
Interestingly, the clinically associated cell signaling
responses at S6 (pS235/pS236) segregated across different
conditions in terms of the respective cell subtypes and
ligands involved. Alterations in T-cell subsets (CD4+ and
CD4−) using calyculin A and PMA/ionomycin were shared
between SCZ and BD, while alterations in B cells using
BCR/CD40L and thapsigargin were unique to MDD
(Table S6). This raises the possibility that the aberrant
responses at S6 (pS235/pS236) in T cells represent a
common feature of psychotic conditions while those present
in B cells are unique to unipolar depression. The fact that
the same epitope is abnormally regulated in different dis-
eases in a mutually exclusive manner, dependent on the cell
subtype and stimulant used, suggests that the epitope itself
is not the sole pathological determinant. Instead, it likely
represents a surrogate endpoint for the integration of
abnormal responses across the signaling network. This is
supported by the fact that the epitopes which showed the
greatest number of clinical associations (S6 (pS235/pS236),
NF-κB p65 (pS529) and Stat3 (pS727)) are all distal
effectors of their respective canonical signaling pathways
(PI3K/mTOR and MAPK/ERK pathways for S6 (pS235/
pS236), IL-1 receptor/Toll-like receptor pathway for NF-κB
p65 (pS529) and JAK/STAT pathway for Stat3 (pS727)).
Concurrently, due to their pleiotropic nature [91, 111, 112],
alterations in the activation state of these cell signaling
proteins have the potential to affect the transcription and
translation of multiple gene products beyond the epitopes
measured.
The network correlation analysis across all ligands
highlighted further dysregulated epitopes and disease
similarities which were not identified by the analysis of
individual node responses, such as reduced activity corre-
lations between CrkL (pY207), Pyk2 (pY402), and Src
(pY418) in CD4+ T cells in SCZ and ASC (Fig. 3). This
suggests that the integration of multiple functional pertur-
bations as changes in network correlation structure can
reveal higher order interactions which are not observable
through the analysis of individual nodes and reflect a range
of potentially pathological signaling states. Interestingly, six
out of eight epitopes which showed altered connectivity in
CD4+ T cells in SCZ (CrkL (pY207), Pyk2 (pY402), Src
(pY418), PKA RIIα (pS99), Akt1, and PLC-γ1; Fig. 3) have
previously been associated with response to in vivo clinical
antipsychotic therapy [25]. This suggests that the explora-
tion of signaling network correlations ex vivo could provide
a novel strategy to identify drug targets with potential
in vivo efficacy. Furthermore, by contrasting the distribu-
tion of epitopes in functional clusters with changes in
individual epitope correlations it is possible to prioritize the
putative drug targets in terms of their potential effects on
network connectivity.
The present results add to the existing evidence of spe-
cific signaling dysregulations in lymphocytes in neu-
ropsychiatric conditions in several ways. First, while
previous studies have suggested abnormal expression of cell
signaling proteins in resting state PBMCs [65], the present
results suggest that basal alterations only account for a
minority (20%) of the total cell signaling alterations
revealed with the additional use of functional stimulation
(Table S6). Furthermore, for nodes which display basal
alterations (e.g., basal Akt1 in B cells in SCZ), functional
stimulation can be used to accentuate the significance of
clinical associations (e.g., calyculin A-Akt1 in B cells in
SCZ). Second, previous work has suggested that immune
dysregulation in neuropsychiatric conditions involves the
composite dysfunction of entire subpopulations of cells
[113] or entire pathways within cells [31], in part due to the
focus on generic endpoints or single proteins as surrogate
markers for whole pathway activation. The fact that the total
number of active ligand responses and their fold change
distributions were similar between different diseases in each
cell subtype (Figure S5 and Table S5) and the number of
clinically associated active nodes (n= 20) represented a
minority (3.4%) of the total active nodes (n= 581), sug-
gests that global functionality per cell subtype is largely
similar across the clinical groups. This is further supported,
at the level of signaling network analysis, by similar cluster
composition and functional correlations between the
majority of epitopes across clinical groups (Fig. 3 and
Figures S6 and S7). Instead, most disease-associated
alterations in cell signaling appeared as specific
ligand–epitope–cell subtype combinations or changes in
individual network connections. These nodes likely repre-
sent specific stress points which escape the regulatory
control of a wider, more tightly regulated, network and as
such represent the most physiologically relevant drug
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targets. Moreover, the results allow the prioritization of
PBMC subtypes which reflect the most relevant models for
future disease investigations. In this respect, it was notable
that the majority of clinically associated cell signaling nodes
were identified in B cells relative to CD4+ or CD4− T cells.
This is consistent with the enrichment of disease-associated
SNPs in B cell subtype-specific promoters in GWAS ana-
lyses of selected neuropsychiatric disorders [11].
Finally, the ultimate utility of the identified peripheral
cell signaling abnormalities as drug targets will depend on
whether they are involved in causal CNS disease mechan-
isms. Parallel protein changes in patient post-mortem brain
studies, behavioral abnormalities in animal knockout/
knockin studies and involvement in the mechanisms of
clinical drug efficacy, described for several of the identified
cell signaling abnormalities, suggest that they may represent
plausible surrogate targets with parallel CNS manifesta-
tions. Alternatively, the identified cell signaling abnormal-
ities may represent direct targets for treating immunological
dysfunctions which can in turn ameliorate brain pathology
through peripheral-CNS crosstalk [27, 78]. This is sup-
ported by the efficacy of adjunctive immunomodulatory
therapies in subgroups of neuropsychiatric patients
[114, 115]. In either case, the likelihood that a subset, but
not all, of blood-based alterations may influence the CNS
and that this may vary across sub-clusters of patients [63],
necessitates further investigations to prioritize the identified
peripheral cell signaling abnormalities in terms of their
potential as novel drug targets. Conversely, candidate
compounds will need to be carefully evaluated to ensure
that drug interactions outside of the target tissue type do not
provoke overt toxicity at the clinical level [116].
While this work aims to provide a proof of principle
application for high-content single cell screening in primary
patient PBMCs across different neuropsychiatric conditions,
several limitations must be taken into account with rele-
vance to future work. First, diagnostic uncertainty and
disease heterogeneity between related neuropsychiatric
conditions [7, 61, 62] are persistent limitations in the current
diagnostic framework. Thus, while study groups were
defined, in the absence of alternatives, using clinical
assessment of DSM-IV-TR criteria [5], this classification
system may potentially be improved by successive incor-
poration of biological markers (such as those proposed here)
which better reflect disease etiology. Second, although the
results were controlled for patient medication status as far as
possible, the MDD and BD groups consisted primarily of
treated patients, limiting interpretation of the results from
these groups to putative trait markers of the disease. Third,
the depicted network connections (Fig. 3, Figures S6 and
S7) represent correlated epitope activity. Further experi-
ments would be required to infer a causative link or direct
biochemical binding between the epitopes. Finally, the
samples sizes used (n= 25 per disease) reflect difficulties in
obtaining viable primary PBMCs from strictly defined and
well-matched neuropsychiatric patient populations. Future
investigations of the identified cell signaling abnormalities
would benefit from the inclusion of larger patient cohorts.
In conclusion, the present results allow the definition of
convergent abnormal cell signaling phenotypes (“functional
cellular endophenotypes”) in ex vivo PBMCs from patients
with different neuropsychiatric diagnoses. These functional
endophenotypes have several potential implications for
understanding the molecular etiology of neuropsychiatric
diseases and defining novel therapeutic targets. First, they
provide a heuristic means to summarize complex genetic
risk as tractable and accessible live cell disease models.
These models can be applied to novel drug screening [25]
and further investigations of disease mechanisms, using
complementary molecular profiling techniques and
response-based cell sorting. Second, they provide a means
for functionally testing clinical drugs against disease-related
cellular phenotypes in live patient samples ex vivo for the
purposes of treatment response prediction and personalized
medicine [25]. Third, as the molecular heterogeneity of
neuropsychiatric diseases becomes increasingly apparent
[61], they offer novel strategies for defining subgroups of
patients with potentially distinct molecular etiology and
pharmacological response profiles. Finally, they provide a
means for discerning functional responses which are unique
to specific conditions (e.g., thapsigargin-S6 (pS235/pS236)
in B cells in MDD) or alternatively shared between condi-
tions (e.g., calyculin A-S6 (pS235/pS236) in CD4− T cells
in SCZ and BD) with subsets of closely related symptoms
(e.g., psychosis and mania respectively). At a time when the
diagnostic framework of neuropsychiatric conditions is
constantly evolving [2], these functional endophenotypes
may serve to facilitate both the redefinition of diagnostic
categories and the elucidation of drug targets and treatment
response predictors which transcend diagnostic boundaries.
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